The drug Symtuza®, a pill to treat infection by the HIV (human immunodeficiency virus), which is administered once a day, and consists of a new combination of five antiretroviral drugs, including darunavir (a protease inhibitor), has just been approved in Spain by the Ministry of Health, Social Services and Equality, after checking its efficacy and safety in two international clinical trials -Amber and Emerald-, in which 276 patients from 21 Spanish centers.

The new antiretroviral therapy, marketed by Janssen-Cilag SA, and which is indicated for adults and adolescents from 12 years of age, has shown a high rate of virological suppression, together with a good tolerability and an accumulated rate of low virological rebound at 48 weeks of administration, both in the case of patients who start treatment, and in those who have already been treated.

Experts say that it is more difficult for HIV to become resistant to this new antiretroviral therapy

Darunavir keeps HIV infection under control

Dr. Eugenia Negredo, assistant physician at the Germans Trias i Pujol Hospital in Badalona and responsible for the research on HIV complications and aging, which has participated in the clinical development of the drug, has explained that darunavir is safe, is tolerated very well, and has a high efficacy that lasts over time, since it is more difficult for HIV to become resistant to this therapy, even in those patients who have been given other previous treatments or have previously developed resistances.

Dr. José Ramón Arribas, director of the Research Group of AIDS and Infectious Diseases at the University Hospital La Paz in Madrid, highlighted the safety profile of this combination of drugs, which reduces bone and kidney toxicity, which reduces the possible limitations of its use. Experts say that the new therapy will keep the infection under control and improve the prognosis and quality of life of patients.

PrEP - an HIV prevention option (November 2019).